tradingkey.logo
tradingkey.logo

Denali Therapeutics Announces U.S. FDA Approval Of Avlayah™ (Tividenofusp Alfa-Eknm) For Treatment Of Hunter Syndrome (Mps Ii)

ReutersMar 25, 2026 4:02 PM

- Denali Therapeutics Inc DNLI.O:

  • DENALI THERAPEUTICS ANNOUNCES U.S. FDA APPROVAL OF AVLAYAH™ (TIVIDENOFUSP ALFA-EKNM) FOR TREATMENT OF HUNTER SYNDROME (MPS II)

  • DENALI THERAPEUTICS INC - AVLAYAH TO BE AVAILABLE IN U.S. SHORTLY AFTER APPROVAL, ADMINISTERED ONCE WEEKLY

  • DENALI THERAPEUTICS INC - AWARDED RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER WITH FDA APPROVAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI